Process Validation Stages 1, 2 and 3 Explained

Process validation is the collection and evaluation of data, from process design through commercial production, that shows a process can consistently deliver product of the required quality. The US FDA's 2011 guidance, Process Validation: General Principles and Practices, divides it into three stages: process design (Stage 1), process qualification (Stage 2) and continued process verification (Stage 3).

This life-cycle model replaced the older idea that validation meant three good batches and a signed report. Validation now starts in development and continues until the product is discontinued.

From three batches to a life cycle

FDA's 2011 guidance replaced its 1987 guideline and built on ICH Q8(R2) on pharmaceutical development, ICH Q9(R1) on quality risk management and ICH Q10 on the pharmaceutical quality system. EU GMP Annex 15, revised in 2015, adopted the same life-cycle thinking with slightly different terms.

The key shift is that confidence comes from process understanding, not a fixed number of batches. You must know which attributes and parameters affect quality, control them, and keep proving the process stays in control.

Stage 1: process design

Stage 1 defines the commercial process from knowledge gained in development and scale-up. Typical activities include:

• Defining the quality target product profile and the critical quality attributes (CQAs).
• Using risk assessment, such as FMEA, to identify potential critical process parameters (CPPs) and material attributes.
• Running designed experiments (DoE) at laboratory or pilot scale to understand how parameters affect CQAs.
• Establishing a control strategy: parameter ranges, in-process controls, specifications and monitoring.

The output is a documented process and control strategy. Stage 1 work need not be performed under full GMP, but it must be scientifically sound and traceable.

Stage 2: process qualification

Stage 2 confirms that the designed process, run in the commercial facility, is capable of reproducible commercial manufacture. FDA describes two elements.

Facility, utility and equipment qualification

Before PPQ, premises, utilities such as purified water and HVAC, and equipment must be qualified through user requirements, design qualification and IQ, OQ, PQ. Cleaning validation and analytical method validation must also be in place.

Process performance qualification (PPQ)

PPQ runs the commercial process at commercial scale, with routine personnel, materials and procedures, under a pre-approved protocol. The protocol defines the batches, sampling plan, tests and statistically justified acceptance criteria. Sampling is heavier than in routine production, for example across a vessel, at the start, middle and end of filling, and during interruptions.

FDA's guidance does not mandate a number of PPQ batches; the number must be justified by process knowledge and risk. Under FDA's approach, PPQ must be successfully completed before commercial distribution of the product, with the report approved by the quality unit.

Stage 3: continued process verification

Stage 3 provides ongoing assurance that the process remains in a state of control during routine production. It involves:

• Collecting and trending data on CQAs, CPPs and in-process results, using statistical tools such as control charts.
• Continuing heightened sampling after PPQ until variability is well understood, then justifying any reduction.
• Reviewing deviations, complaints, OOS results and yield trends for signals of drift.
• Feeding results into the annual product review and into change control when improvements are made.

A Stage 3 signal may lead to an investigation, CAPA, or a return to Stage 1 or 2 if the process changes significantly. Stage 3 data are summarised each year in the annual product quality review.

The three stages at a glance

How EU GMP Annex 15 describes the same ideas

Annex 15 recognises three approaches to validating a process. Traditional process validation runs a number of batches under routine conditions; Annex 15 notes that a minimum of three consecutive batches is generally considered acceptable, though another number may be justified. Continuous process verification is an alternative where the process is designed with enhanced understanding and monitored in real time, for example using process analytical technology. A hybrid approach combines the two.

Whatever approach is used, Annex 15 expects ongoing process verification throughout the product life cycle, which corresponds closely to FDA's Stage 3. Annex 15 also allows concurrent validation only in exceptional, justified circumstances. WHO GMP and India's revised Schedule M contain broadly similar expectations, so check the current text for each market.

Worked example: launching an oral liquid

A plant in Ras Al Khaimah is launching a preserved paediatric oral solution for GCC markets, made in a 2,000 L vessel and filled into amber bottles.

1. Stage 1: CQAs include assay, preservative content, pH, viscosity, related substances, microbial quality and fill volume. Risk assessment flags temperature at preservative addition, mixing time and hold time before filling. Pilot-scale DoE shows preservative content is sensitive to addition temperature, so the control strategy sets a tight temperature range.
2. Stage 2a: the vessel, transfer line and filling line are qualified, and cleaning validation covers the new product.
3. Stage 2b: the PPQ protocol justifies three consecutive commercial batches based on risk and Stage 1 knowledge. Samples are taken from the top, middle and bottom of the vessel and from the start, middle and end of filling. All results meet acceptance criteria; one batch shows viscosity near the upper limit, traced to a slower thickener addition. The batch record instruction is clarified through change control.
4. Stage 3: heightened sampling continues for the early commercial batches while control charts are built for assay, preservative, pH and viscosity. Months later, preservative results trend downward. Investigation finds a drifting vessel temperature probe, which is recalibrated, and the calibration interval is reviewed.

Without Stage 3 trending, that drift would have surfaced later as a stability or release failure.

Common mistakes

• Treating three PPQ batches as automatic, without a documented justification.
• Starting PPQ before equipment, utilities, cleaning and methods are qualified or validated.
• Using routine sampling during PPQ, which cannot show within-batch variability.
• Stopping heightened monitoring after PPQ without statistical evidence.
• Running Stage 3 as a filing exercise, with charts that nobody reviews.
• Confusing FDA continued process verification with EU continuous process verification.

Key takeaway: Process validation is a life cycle, not a one-off event. Design the process with understanding, qualify it at commercial scale with justified sampling, and keep verifying it with trended data for as long as the product is made.

Frequently Asked Questions

What are the three stages of process validation?

Under FDA's 2011 guidance, Stage 1 is process design, where the commercial process and control strategy are defined. Stage 2 is process qualification, covering facility, utility and equipment qualification and process performance qualification. Stage 3 is continued process verification, which confirms during routine production that the process stays in a state of control.

How many batches are needed for PPQ?

FDA's guidance does not set a fixed number; the number must be justified by process knowledge, variability and risk. For traditional validation, EU GMP Annex 15 notes that a minimum of three consecutive batches is generally considered acceptable, but another number may be justified. Check the current guidance and any market-specific expectations.

What is the difference between continued and ongoing process verification?

They describe the same idea in different guidance. Continued process verification is FDA's Stage 3, and ongoing process verification is the EU Annex 15 term. Both mean collecting and evaluating data during routine production to confirm the process remains in control. Do not confuse either with EU continuous process verification, an alternative validation approach.

Is process validation the same as equipment qualification?

No. Equipment qualification shows that equipment is installed correctly, operates as specified and performs consistently. Process validation shows that the whole manufacturing process, using qualified equipment, utilities, materials and people, consistently delivers product meeting its quality attributes. Qualification is a prerequisite for, and part of, Stage 2 of process validation.

Next steps

Our Regulatory Affairs for Pharma & Medical Devices in the GCC course explains how validation data support registration dossiers, and Root Cause Analysis & CAPA builds the investigation skills that Stage 3 signals demand. For related reading, see IQ, OQ, PQ explained, deviation vs change control vs CAPA and GMP vs cGMP. If you would like help choosing, speak to a counsellor.